Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Cephalalgia : an International Journal of Headache|April 25, 2024
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraineRobert Croop, Gary Berman, David Kudrow, et al.
Headache|September 16, 2022
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonistDavid Kudrow, Linda Nguyen, Jack Semler, et al.
Headache|January 17, 2020
Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for LasmiditanDavid Kudrow, John H Krege, Hans P Hundemer, et al.
BMC Neurology|March 15, 2020
Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studiesMark E Bangs, David Kudrow, Shufang Wang, et al.
Headache|August 18, 2020
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for MigraineGary Berman, Robert Croop, David Kudrow, et al.
Pain and Therapy|April 17, 2026
Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL TrialAmaal J Starling, David Kudrow, Neha Kapur, et al.
Cephalalgia : an International Journal of Headache|November 23, 2019
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraineJan Lewis Brandes, David Kudrow, Paul P Yeung, et al.
BMC Neurology|January 19, 2020
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studiesMark E Bangs, David Kudrow, Shufang Wang, et al.
Cephalalgia : an International Journal of Headache|August 22, 2019
Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)Jan Lewis Brandes, Suzanne Klise, John H Krege, et al.
Headache|November 12, 2020
Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster HeadacheDavid Kudrow, J Scott Andrews, Mallikarjuna Rettiganti, et al.
Pageof 4